Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nanjing Bostec Biological Engineering Co. Ltd. is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by a distinct examiner, PURDY, KYLE A, who is identified as the busiest examiner. The prosecution is concentrated within 1 distinct art unit, reflecting a specific focus for the company's current patent activity.
In the Biotechnology & Pharmaceuticals sector, having only 1 pending office action means the company's immediate patent office interaction is limited to a point of contact. The involvement of PURDY, KYLE A suggests that the prosecution strategy can be highly tailored to the specific feedback provided by the examiner. This streamlined profile minimizes the complexity often found in larger biotech portfolios. Practitioners should focus on the specific standards of the 1 distinct art unit and the individual tendencies of PURDY, KYLE A to navigate the prosecution of this application successfully.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PURDY, KYLE A | 1 | 41.0% | +35.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18995916 | NATURAL PORPHIN SALT AND USE THEREOF AS PLANT GROWTH REGULATOR AND PLANT IMMUNITY INDUCER | PURDY, KYLE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18995916 | NATURAL PORPHIN SALT AND USE THEREOF AS PLANT GROWTH REGULATOR AND PLANT IMMUNITY INDUCER | PURDY, KYLE A | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18995916 | NATURAL PORPHIN SALT AND USE THEREOF AS PLANT GROWTH REGULATOR AND PLANT IMMUNITY INDUCER | PURDY, KYLE A | 1611 | §101§102§112 | Non-Final OA | — | Pending | Jan 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanjing Bostec Biological Engineering Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kyle A Purdy has the most, with 1 of Nanjing Bostec Biological Engineering Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
